Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Rating of “Buy” from Brokerages

Vera Therapeutics, Inc. (NASDAQ:VERA) has been given an average rating of “Buy” by the eight research firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $32.29.

Several brokerages have recently weighed in on VERA. Oppenheimer initiated coverage on Vera Therapeutics in a report on Thursday, January 25th. They issued an “outperform” rating and a $26.00 price objective for the company. Wedbush upped their price objective on Vera Therapeutics from $21.00 to $34.00 and gave the stock a “neutral” rating in a research note on Thursday, March 21st. Raymond James raised shares of Vera Therapeutics from an “outperform” rating to a “strong-buy” rating and raised their target price for the company from $29.00 to $37.00 in a research note on Friday, January 26th. Cantor Fitzgerald initiated coverage on shares of Vera Therapeutics in a research note on Monday, January 8th. They issued an “overweight” rating for the company. Finally, Guggenheim reissued a “buy” rating and issued a $56.00 price objective on shares of Vera Therapeutics in a research report on Friday, April 5th.

Vera Therapeutics Stock Down 3.2 %

Shares of Vera Therapeutics stock opened at $38.69 on Friday. Vera Therapeutics has a 52-week low of $6.07 and a 52-week high of $50.78. The company has a debt-to-equity ratio of 0.49, a quick ratio of 7.71 and a current ratio of 7.71. The business’s 50 day simple moving average is $43.24 and its 200 day simple moving average is $26.66. The firm has a market cap of $2.11 billion, a PE ratio of -16.90 and a beta of 1.05.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Wednesday, March 20th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.05). On average, analysts predict that Vera Therapeutics will post -2.18 earnings per share for the current fiscal year.

Insider Buying and Selling at Vera Therapeutics

In related news, SVP Joseph R. Young sold 5,714 shares of Vera Therapeutics stock in a transaction dated Wednesday, April 10th. The shares were sold at an average price of $40.00, for a total transaction of $228,560.00. Following the completion of the sale, the senior vice president now owns 53,171 shares of the company’s stock, valued at approximately $2,126,840. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, SVP Joseph R. Young sold 5,714 shares of Vera Therapeutics stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $40.00, for a total transaction of $228,560.00. Following the completion of the sale, the senior vice president now directly owns 53,171 shares of the company’s stock, valued at approximately $2,126,840. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Maha Katabi acquired 161,290 shares of the firm’s stock in a transaction on Tuesday, January 30th. The stock was purchased at an average cost of $31.00 per share, for a total transaction of $4,999,990.00. Following the completion of the acquisition, the director now owns 3,628,446 shares in the company, valued at $112,481,826. The disclosure for this purchase can be found here. Insiders have sold a total of 526,551 shares of company stock worth $21,533,345 over the last ninety days. Insiders own 21.70% of the company’s stock.

Hedge Funds Weigh In On Vera Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Vera Therapeutics during the 3rd quarter worth approximately $79,000. Mirae Asset Global Investments Co. Ltd. grew its position in Vera Therapeutics by 27.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 20,579 shares of the company’s stock worth $282,000 after buying an additional 4,387 shares in the last quarter. Barclays PLC grew its position in Vera Therapeutics by 964.6% during the third quarter. Barclays PLC now owns 71,703 shares of the company’s stock worth $983,000 after buying an additional 64,968 shares in the last quarter. Amalgamated Bank increased its stake in Vera Therapeutics by 26.0% during the 3rd quarter. Amalgamated Bank now owns 4,189 shares of the company’s stock worth $57,000 after acquiring an additional 864 shares during the period. Finally, Swiss National Bank acquired a new position in Vera Therapeutics in the 3rd quarter valued at $668,000. 99.21% of the stock is owned by institutional investors.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.